Mr David Wurzer

KANDO id: 42320

Bio

Dave joined Connecticut Innovations in 2009. He is responsible for sourcing and analyzing investment opportunities, leading CI investments in entrepreneurial high-tech ventures and advising portfolio companies. Dave serves on the boards of CI portfolio companies Axerion Therapeutics, CyVek, Post-n-Track, Semantifi and Weston Software, and on the boards of DUSA Pharmaceuticals (NASDAQ GM:DUSA) Response Genetics (NASDAQ: RGDX), and Strategic Diagnostics d/b/a SDIX (NASDAQ:SDIX). Dave came to CI with extensive senior-level experience in operations and finance. Most recently, he was executive vice president, treasurer and chief financial officer of CuraGen Corporation (NASDAQ: CRGN), a former CI portfolio company. Dave guided the biotech company through its initial public offering and helped raise over $700 million for the company. Dave was also involved in negotiating strategic and business development alliances with several pharmaceutical and biotech companies, including Roche, Bayer, and Amgen-Freemont (Abgenix). He helped to grow CuraGen and its technology development subsidiary into an operation with over 500 employees and a market capitalization as high as $5.3 billion. Previously, Dave served as senior vice president, treasurer and chief financial officer of Value Health Inc. (NYSE:VH), a specialty managed health care company. He helped the company achieve exceptional growth, actively participating in multiple acquisitions and public offerings and the sale of the company to Columbia/HCA for $1.1 billion. Dave began his professional career with Coopers & Lybrand in Hartford, Conn. (now part of PricewaterhouseCoopers), where he held various accounting and managerial positions. He is a certified public accountant and holds a Bachelor of Business Administration in Accountancy degree from the University of Notre Dame.

Education